Publicaciones en las que colabora con Ana Lluch Hernández (9)

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

2003

  1. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer

    Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291

  2. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy

    Leukemia, Vol. 17, Núm. 2, pp. 437-441

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743

1997

  1. Estudio multicéntrico prospectivo, randomizado del papel del filgrastim (G-CSF) post trasplante de progenitores hematopoyéticos movilizados con G-CSF en pacientes con cáncer de mama.

    Sangre, Vol. 42 Suppl 1, pp. 54-56

  2. Quimioterapia en dosis altas y trasplante autólogo de células germinales hematopoyéticas de sangre periférica en el carcinoma de mama de alto riesgo de recaída (con > = or 10 ganglios axilares afectos al diagnóstico). Resultados preliminares del estudio cooperativo Solti 9301. El Grupo SOLT1.

    Sangre, Vol. 42 Suppl 1, pp. 53-56